Last reviewed · How we verify
Placebo Match to SH D593B
Placebo Match to SH D593B is a Small molecule drug developed by Bayer. It is currently in Phase 3 development.
This is a placebo formulation designed to match the physical and sensory characteristics of the active investigational drug SH D593B in clinical trials.
At a glance
| Generic name | Placebo Match to SH D593B |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo match formulations are inactive comparators used in blinded clinical trials to maintain study integrity by appearing identical to the active drug in appearance, taste, texture, and administration route. This ensures that neither patients nor some study staff can identify whether they are receiving active treatment or placebo, reducing bias in efficacy and safety assessments.
Approved indications
Common side effects
Key clinical trials
- Effect on Primary Dysmenorrhea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Match to SH D593B CI brief — competitive landscape report
- Placebo Match to SH D593B updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Placebo Match to SH D593B
What is Placebo Match to SH D593B?
How does Placebo Match to SH D593B work?
Who makes Placebo Match to SH D593B?
What development phase is Placebo Match to SH D593B in?
Related
- Manufacturer: Bayer — full pipeline
- Compare: Placebo Match to SH D593B vs similar drugs
- Pricing: Placebo Match to SH D593B cost, discount & access